Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

The triterpenoid CDDO-Me inhibits bleomycin-induced lung inflammation and fibrosis.

Kulkarni AA, Thatcher TH, Hsiao HM, Olsen KC, Kottmann RM, Morrissette J, Wright TW, Phipps RP, Sime PJ.

PLoS One. 2013 May 31;8(5):e63798. doi: 10.1371/journal.pone.0063798. Print 2013.

2.

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.

Wang YY, Yang YX, Zhe H, He ZX, Zhou SF.

Drug Des Devel Ther. 2014 Oct 23;8:2075-88. doi: 10.2147/DDDT.S68872. eCollection 2014. Review.

3.

Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment.

Wang YY, Zhe H, Zhao R.

Mol Cancer. 2014 Feb 20;13:30. doi: 10.1186/1476-4598-13-30. Review.

4.

Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review.

Srour N, Th├ębaud B.

Stem Cells Transl Med. 2015 Dec;4(12):1500-10. doi: 10.5966/sctm.2015-0121. Epub 2015 Oct 22. Review.

5.

CDDO and Its Role in Chronic Diseases.

Mathis BJ, Cui T.

Adv Exp Med Biol. 2016;929:291-314. Review.

PMID:
27771930
6.

Mechanisms of bleomycin-induced lung damage.

Hay J, Shahzeidi S, Laurent G.

Arch Toxicol. 1991;65(2):81-94. Review.

PMID:
1711838
7.

The IL-1 cytokine family and its role in inflammation and fibrosis in the lung.

Borthwick LA.

Semin Immunopathol. 2016 Jul;38(4):517-34. doi: 10.1007/s00281-016-0559-z. Epub 2016 Mar 21. Review.

Supplemental Content

Support Center